Fundz

Arbutus Biopharma Appoints Karen Sims as Chief Medical Officer (NASDAQ:ABUS) | Seeking Alpha

PUBLIC · ABUSJul 11, 2023

Position

Chief Medical Officer

Company

Arbutus

Karen Sims
ksims@arbutusbio.com
WarminsterBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma

Description

{}

Quick answer

Arbutus Biopharma Appoints Karen Sims as Chief Medical Officer (NASDAQ:ABUS) | Seeking Alpha (July 11, 2023). Arbutus is based in Warminster, Pennsylvania, United States.

Who is the new Chief Medical Officer at Arbutus?
Arbutus named Karen Sims Chief Medical Officer, announced July 11, 2023.
What did Arbutus announce on July 11, 2023?
{}
What does Arbutus do?
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which...
Where is Arbutus based?
Arbutus is based in Warminster, Pennsylvania, United States.
Which similar companies made leadership changes around the same time?
MBX Biosciences, Inc. (July 10, 2023), AbbVie Inc. (June 29, 2023), Verastem Oncology (July 11, 2023) and EyePoint, Inc. (July 10, 2023) also announced leadership changes within 45 days of Arbutus.

Source: Fundz verified event record.

Other recent leadership changes in Healthcare and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Arbutus, and when

A new leader at Arbutus brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Arbutus raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Arbutus, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Arbutus. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Arbutus

Location

701 Veterans Circle

Warminster, Pennsylvania, United States

About

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729) and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. Additionally, we have identified compounds in our internal PD-L1 portfolio that could also be used in oncology indications. For more information, visit www.arbutusbio.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Arbutus changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Karen
Likely contact at this company
••••••••@••••••••

See Karen's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Arbutus's next move

Learn about Strategic plan

Arbutus changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.